TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06520345: The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)

Sponsor: Telix Pharmaceuticals (Innovations) Pty Limited · Phase: PHASE3 · Area: ONCOLOGY · Target Enrollment: 520 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$787,248

Rescue Site Savings

+$524,832

Unlock Full NCT06520345 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06520345 Rescue Dossier →